Bayer's Trasylol Increases Risk Of Death: Study
Just weeks after Bayer AG yanked the leftover stock of its blood-clotting drug Trasylol from the U.S. market, a newly published study has revealed that patients receiving the drug have a...To view the full article, register now.
Already a subscriber? Click here to view full article